{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-54","upperLimit":"369","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"An increase in CD4 cells is determined by the number of CD4+ T lymphocytes /µL of peripheral blood.","dispersionType":"Full Range","groups":[{"description":"Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.\n\nMethotrexate: 6000 mg/m\\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.\n\nRituximab: 375 mg/m\\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate\n\nLeucovorin: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes","id":"OG000","title":"Rituximab, High-Dose Methotrexate & Leucovorin Treatment"}],"paramType":"MEDIAN","populationDescription":"Two participants were not evaluable. One participant received one cycle of therapy and one was not evaluable due to treatment failure.","reportingStatus":"POSTED","timeFrame":"Baseline and up to 2.5 years","title":"Change From Baseline in Cluster of Differentiation 4 (CD4) T Cell Count at up to 2.5 Years","type":"SECONDARY","unitOfMeasure":"cells/µL"}